Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 1

Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC

,

Panelists discuss how, when discussing frontline regimens for EGFR-mutated non–small cell lung cancer (NSCLC), the NCCN-recommended options include osimertinib monotherapy for its targeted approach with lower toxicity; amivantamab/lazertinib combination for potentially deeper responses in specific mutations; and osimertinib with platinum-doublet chemotherapy for more aggressive disease requiring enhanced tumor control.

Now Viewing
EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC
EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification
EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC
EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC
EP. 7: Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC
EP. 8: Future Treatment Options in EGFR-Mutant NSCLC

Video content above is prompted by the following:

  • When discussing initial treatment options, how do you present the 3 recommended NCCN frontline regimens to patients: osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with a platinum-containing doublet?

Related Content:

Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLCVideo SeriesClinicalLung Cancer
The OncFive: Top Oncology Articles for the Week of 12/7
Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC
Multidisciplinary Collaboration to Improve Early Recognition and Care For CA-LEMS